Anyone who is allergic to compounded GLP-1 therapy, or other ingredients found in compounded GLP-1 therapy is not a good candidate
As it turns out, they also lead to weight loss, though per the Mayo Clinic, the official reason for this weight loss is unknown
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study
By week 8 to 12, youll likely start noticing weight loss
Strokes are mostly caused by arterial occlusion, which in turn leads to cerebral ischemia, brain damage, and then nerve damage and disability
Before adjusting your semaglutide or tirzepatide regimen, track your food intake for one week, assess your activity level, and confirm you're sleeping 79 hours nightly